Published in Gene Therapy Weekly, December 22nd, 1997
This patent is one of numerous intellectual properties owned by The Board of Regents of UT and licensed exclusively to Introgen Therapeutics, Inc. through Introgen's broad license agreement with UT's M.D. Anderson Cancer Center (UTMDACC). The p16 gene...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.